The effect of Liple® on physical and emotional quality of life in the treatment of arteriosclerosis obliterans

International Angiology

Volumn 23, Issue 3, 2004, Pages 238-245

  Fukuhara, S ^a,c   Esato, K ^b  

^a KYOTO UNIVERSITY   (Japan)

^b Yamaguchi Prefectural Hospital   (Japan)

^c NONE   (Japan)

Author keywords

Arteriosclerosis; Arteriosclerosis obliterans; Liple; Prostaglandin E1; Quality of life; SF 36

Indexed keywords

ANALGESIC AGENT; LIPOPROSTAGLANDIN E1; NONSTEROID ANTIINFLAMMATORY AGENT; VASODILATOR AGENT; FIBRINOLYTIC AGENT; PROSTAGLANDIN E1;

ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EMOTION; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; JAPAN; LEG PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PAIN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; TREATMENT OUTCOME; DRUG EFFECT; HEALTH STATUS; MIDDLE AGED; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; SICKNESS IMPACT PROFILE; WALKING;

ADOLESCENT; ADULT; AGED; ALPROSTADIL; ARTERIOSCLEROSIS OBLITERANS; FEMALE; FIBRINOLYTIC AGENTS; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME; WALKING;

EID: 11844249298     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. 1 in severe peripheral vascular disease. Lancet 1976;2:810.
2. 1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular disease in man. J Pharm Pharmacol 1983;35:666-7.
3. Fukuhara S, Suzukamo Y, Bito S, Kurokawa K. Manual of SF-36 Japanese Version 1.2. Tokyo: Public Health Research Foundation; 2001.
4. Fukuhara S, Ware JE, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998;51:1045-53.
5. Ware JE, Sherboune CD. The MOS 36-item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30:473-89.
6. Stewart AL, Ware JE. Measuring functioning and well-being. The medical outcomes study approach. Durham, NC: Duke University Press; 1992.
7. McHorney CA, Ware JE, Raczek AE. The MOS 36-item Short-Form Health Survey (SF-36): II. Psychometric and clinical test of validity in measuring and mental health constructs. Med Care 1993;31:247-63.
8. McHorney CA, Ware JE, Raczek AE. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.